Practical management of patients with ch
β
Francisco Cervantes; Michael Mauro
π
Article
π
2011
π
John Wiley and Sons
π
English
β 175 KB
## Abstract Although imatinib has been used as frontline therapy for chronic myeloid leukemia (CML) for nearly a decade, current debate is focused on the incorporation of newer tyrosine kinase inhibitors (TKIs) at diagnosis in light of recent US Food and Drug Administration approval of nilotinib an